United States Patent 8,618,130: A Detailed Analysis of Scope, Claims, and Patent Landscape
Introduction
The United States Patent 8,618,130, titled "Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases," is a significant patent held by ACADIA Pharmaceuticals Inc. This patent is crucial for understanding the therapeutic applications of selective serotonin 2A/2C receptor inverse agonists, particularly in the context of neurodegenerative diseases.
Patent Overview
Issuance and Expiration
The patent was issued on December 31, 2013, and is set to expire on January 15, 2024[2][4][5].
Inventors and Assignee
The inventors listed on the patent include David M. Weiner, Robert E. Davis, Mark R. Brann, Carl-Magnus A. Andersson, and Allan K. Uldam. The assignee is ACADIA Pharmaceuticals Inc., based in San Diego, California[1][5].
Scope of the Patent
Therapeutic Applications
The patent focuses on the use of selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases. This includes conditions such as Parkinson's disease, where these compounds can help manage hallucinations and delusions associated with the disease[4].
Mechanism of Action
The compounds in question act as inverse agonists at the serotonin 2A and 2C receptors. This mechanism is distinct from traditional antipsychotics and offers a targeted approach to treating neurological symptoms without the full range of side effects associated with broader receptor activity[1].
Claims of the Patent
Key Claims
The patent includes several key claims that define the scope of the invention:
- Chemical Structure: The patent specifies the chemical structures of the selective serotonin 2A/2C receptor inverse agonists.
- Pharmaceutical Compositions: Claims cover the formulation of these compounds into pharmaceutical compositions suitable for administration.
- Therapeutic Uses: The patent claims the use of these compounds for treating neurodegenerative diseases, including Parkinson's disease[1][5].
Claim Language and Scope
The claim language is critical in defining the breadth and specificity of the patent. The patent scope is measured by metrics such as independent claim length and count, which can indicate the complexity and breadth of the claims. Narrower claims, as seen in this patent, are often associated with a higher probability of grant and shorter examination processes[3].
Patent Landscape
Related Patents
The patent 8,618,130 is part of a broader portfolio of patents held by ACADIA Pharmaceuticals Inc. related to selective serotonin 2A/2C receptor inverse agonists. Other relevant patents include:
- Patent 9,566,271: Also issued to ACADIA Pharmaceuticals Inc., this patent covers similar therapeutic applications and is set to expire on the same date as 8,618,130[2][5].
- Patent 10,028,944: This patent, issued in 2018, extends the coverage to additional compounds and therapeutic uses, with an expiration date in 2038[5].
Litigation and Regulatory Status
The patent has been involved in litigation, particularly in the context of generic drug approvals. For example, litigation was initiated against MSN Laboratories Private Ltd. and MSN Pharmaceuticals, Inc., regarding the infringement of related patents, including the '740 patent[2].
Generic Availability
The expiration of the patent on January 15, 2024, will pave the way for generic versions of the drug, assuming no further extensions or litigation delays. Generic availability is contingent on the resolution of any ongoing litigation and the expiration of other related patents[2][5].
Impact on Neurodegenerative Diseases
Clinical Significance
The compounds covered by this patent, such as pimavanserin, have shown significant clinical benefits in managing hallucinations and delusions in patients with Parkinson's disease. This targeted therapeutic approach has improved the quality of life for many patients by reducing the burden of these symptoms[4].
Future Research Directions
The expiration of this patent and related ones may open up new avenues for research and development, as more companies can explore these compounds and their derivatives. This could lead to further innovations in the treatment of neurodegenerative diseases.
Conclusion
The United States Patent 8,618,130 is a pivotal patent in the field of neurodegenerative disease treatment, particularly for Parkinson's disease. Its focus on selective serotonin 2A/2C receptor inverse agonists has led to significant therapeutic advancements. As the patent landscape evolves with the expiration of this and related patents, we can expect further innovation and potentially more accessible treatments.
Key Takeaways
- Patent Expiration: The patent expires on January 15, 2024.
- Therapeutic Use: The patent covers the use of selective serotonin 2A/2C receptor inverse agonists for neurodegenerative diseases.
- Assignee: ACADIA Pharmaceuticals Inc. is the assignee.
- Related Patents: Part of a broader portfolio of related patents.
- Clinical Impact: Significant benefits in managing hallucinations and delusions in Parkinson's disease patients.
FAQs
What is the primary therapeutic application of the compounds covered by this patent?
The primary therapeutic application is the treatment of hallucinations and delusions associated with neurodegenerative diseases, particularly Parkinson's disease.
Who are the inventors listed on the patent?
The inventors include David M. Weiner, Robert E. Davis, Mark R. Brann, Carl-Magnus A. Andersson, and Allan K. Uldam.
What is the mechanism of action of the compounds described in the patent?
The compounds act as selective serotonin 2A/2C receptor inverse agonists.
What is the current status of generic availability for the drug covered by this patent?
Generic availability is contingent on the expiration of the patent and the resolution of any ongoing litigation, with the patent set to expire on January 15, 2024.
How does the patent landscape affect future research and development in this area?
The expiration of this and related patents may open up new research and development opportunities as more companies can explore these compounds and their derivatives.
